Anticoagulants

Anticoagulants Market Size will Reach USD 70 Billion by 2030

According to Precedence Research, during the forecast period of 2022 to 2030, the global anticoagulants market is estimated to develop at a compound annual growth rate (CAGR) of 9.09%. The global anticoagulants market was valued at USD 32 billion in 2021, and it is predicted to exceed USD 70 billion by 2030. The study investigates several elements and their consequences on the growth of the anticoagulants market.

Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1796

This report focuses on anticoagulants market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall anticoagulants market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.

The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

In-Depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of anticoagulants, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of anticoagulants has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the anticoagulants market.

Some of the prominent players in the anticoagulants market include:

  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Aspen Holdings
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Portola Pharmaceuticals

Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1796

Segments Covered in the Report

By Indication of disease

  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation
  • Heart Attacks
  • Others

By Administration Route

  • Oral
  • Injectable

By Drug Class

  • NOACs
    • Eliquis
    • Bevyxxa
    • Xarelto
    • Savaysa & lixiana
    • Pradaxa
  • Heparin & LMWH
  • Vitamin K Antagonist
  • Others

By Distribution Channel 

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacy
  • Others

Regional Segmentation

  • Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
  • Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
  • North America [United States, Canada, Mexico]
  • South America [Brazil, Argentina, Columbia, Chile, Peru]
  • Middle East & Africa [GCC, North Africa, South Africa]

Some of the important ones are:

  • What can be the best investment choices for venturing into new product and service lines?
  • What value propositions should businesses aim at while making new research and development funding?
  • Which regulations will be most helpful for stakeholders to boost their supply chain network?
  • Which regions might see the demand maturing in certain segments in near future?
  • What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
  • Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
  • Which government regulations might challenge the status of key regional markets?
  • How will the emerging political and economic scenario affect opportunities in key growth areas?
  • What are some of the value-grab opportunities in various segments?
  • What will be the barrier to entry for new players in the market?

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anticoagulants Market 

5.1. COVID-19 Landscape: Anticoagulants Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anticoagulants Market, By Indication of disease

8.1. Anticoagulants Market, by Indication of disease, 2022-2030

8.1.1. Pulmonary Embolism (PE)

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Deep Vein Thrombosis (DVT)

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Atrial Fibrillation

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Heart Attacks

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Anticoagulants Market, By Administration Route

9.1. Anticoagulants Market, by Administration Route e, 2022-2030

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Injectable

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Anticoagulants Market, By Drug Class 

10.1. Anticoagulants Market, by Drug Class, 2022-2030

10.1.1. NOACs

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Heparin & LMWH

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Vitamin K Antagonist

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Anticoagulants Market, By Distribution Channel 

11.1. Anticoagulants Market, by Distribution Channel, 2022-2030

11.1.1. Hospitals Pharmacies

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Online Pharmacy

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Anticoagulants Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.1.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.1.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.2.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.2.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.3.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.3.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.4.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.4.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Johnson & Johnson

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bristol-Myers Squibb Company

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Daiichi Sankyo Company

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Bayer AG

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. BoehringerIngelheim GmbH

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Aspen Holdings

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. GlaxoSmithKline Plc

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Pfizer Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sanofi S.A.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Portola Pharmaceuticals

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1796

About Us

Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.

From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.

Contact Us:                  

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *